U.S. markets open in 13 minutes
  • S&P Futures

    3,812.75
    -4.00 (-0.10%)
     
  • Dow Futures

    31,267.00
    +31.00 (+0.10%)
     
  • Nasdaq Futures

    12,655.00
    -26.75 (-0.21%)
     
  • Russell 2000 Futures

    2,201.30
    -4.50 (-0.20%)
     
  • Crude Oil

    62.39
    +1.11 (+1.81%)
     
  • Gold

    1,714.00
    -1.80 (-0.10%)
     
  • Silver

    26.09
    -0.29 (-1.11%)
     
  • EUR/USD

    1.2041
    -0.0026 (-0.22%)
     
  • 10-Yr Bond

    1.4810
    +0.0110 (+0.75%)
     
  • Vix

    26.15
    +2.05 (+8.51%)
     
  • GBP/USD

    1.3966
    +0.0013 (+0.09%)
     
  • USD/JPY

    107.4500
    +0.4480 (+0.42%)
     
  • BTC-USD

    49,555.12
    -2,555.78 (-4.90%)
     
  • CMC Crypto 200

    993.15
    +5.94 (+0.60%)
     
  • FTSE 100

    6,651.12
    -24.35 (-0.36%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 5118404. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005993/en/

Contacts

Investor & Media Contact:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377